Thiosemicarbazone derivate protects from AAPH and Cu2+-induced LDL oxidation

LIFE SCIENCES

卷:89

Article

Barcelos, Romulo Pillon¹  Portella, Rafael de Lima¹  Flores da Rosa, Edovando Jose¹  Fonseca, Alexandra de Souza²  Bresolin, Leandro²  Carratu, Vanessa²  Antunes Soares, Felix Alexandre¹  Barbosa, Nilda Vargas¹ 

[1] Univ Fed Santa Maria, Dept Quim, Ctr Ciencias Nat & Exatas, BR-97119900 Santa Maria, RS, Brazil

[2] Fundacao Univ Rio Grande, Dept Quim, Rio Grande, RS, Brazil

关键词: LDL oxidation;    Thiosemicarbazone;    Atherosclerosis;    Antioxidant compounds;    Serum oxidation;   

DOI  :  10.1016/j.lfs.2011.04.026

来源: Elsevier

【 摘 要 】

Aims: Several lines of evidence support the hypotheses that the oxidation of low density lipoprotein (LDL) may play a crucial role in the initiation and progression of atherosclerosis. Oxidative stress is one of the causes of the overproduction of reactive species that increase the formation of oxidized LDL Thiosemicarbazones are compounds used in anticancer, antiviral and antifungal therapy; however, its redox activity has been controversial. Thus, we tested, in vitro, a possible antioxidant activity of a thiosemicarbazone derivate, the isatin-3-N-4-benzilthiosemicarbazone (IBTC). Main methods: We measured the conjugated diene formation in serum and LDL as well as the loss of tryptophan fluorescence in LDL induced by two oxidant agents, 2,2-azobis(2-amidinopropane dihydrochloride) (AAPH) and Cu2+. Thiobarbituric acid reactive substances (TBARS) formation in LDL and in different rat tissues was also assessed. The toxicity of IBTC was measured using aortic slices viability assay. Key findings: Our results show that IBTC significantly reduced the AAPH and Cu2+-induced formation of conjugated dienes, increased in a dose-dependent manner the lag phase and the t(1/2) of tryptophan fluorescence, and reduced the TBARS formation in LDL plasma and rat tissues, showing no toxicity to aortic slices. Significance: These results indicate that IBTC is a good antioxidant and a promising antiatherogenic agent for further studies in vivo. (C) 2011 Elsevier Inc. All rights reserved.

【 授权许可】

Free